Patient Satisfaction and Quality of Life Among Adult Women with Androgenetic Alopecia Using 5% Topical Minoxidil

BACKGROUND: Androgenetic alopecia (AGA) is a common, genetically predisposed condition that begins after puberty and whose frequency increases with age; although biologically benign, AGA can impact patients both psychologically and socially, contributing to an impairment on their quality of life. OBJECTIVE: We sought to evaluate the psychological, social, and quality of life impairments inherent in women with AGA using 5% minoxidil daily for at least six months. DESIGN: Thirty-one women with diffuse central hair thinning and shaft miniaturization who were using 5% minoxidil daily for at least six months responded to a clinical questionnaire and underwent trichoscopy. RESULTS: 83.9 percent (n=26) of the participants reported they were satisfied with the 5% minoxidil treatment and its convenience. Hair loss influenced social life in 54.8 percent (n=17) of the respondents and choice of hair cut/hairstyle in 87.1 percent (n=27) of respondents. For 51.6 percent (n=16) hair loss was slightly increased, although it did not increase after beginning treatment. A frontoparietal pattern (74.2%, n=23), very low capillary density (61.3%, n=19), trichodynia (32.3%, n=10), and negative traction test (100%, n=31) were also observed. Miniaturization occurred in 100 percent (n=31) of patients, frontal/occipital hair thickness was reduced in 83.9 percent (n=26), and more than 10 percent of velus hair in the frontal area was observed in 83.9 percent (n=26) of patients. The number of hair shafts per follicular unit was reduced in 67.7 percent (n=21), and a higher frontal to occipital ratio of follicular units with one hair shaft was seen in 74.2 percent (n=23) of patients. Empty follicles, large numbers of peripillar brownish halo, scalp pigmentation, mild Ludwig''s baldness degree, and quality of life scores of 4±3.5 points were observed. CONCLUSION: Our results indicate that patient satisfaction and quality of life of women with AGA on 5% topical minoxidil are high, although hair loss influences daily habits and social life.     

Minoxidil 2% lotion for eyebrow enhancement: A randomized,double‐blind,placebo‐controlled,spilt‐face comparative study

Topical minoxidil has been successfully used to treat androgenetic alopecia. It can also be applied to enhance eyebrows. However, there is no study comparing minoxidil lotion with placebo for eyebrow enhancement. In this trial, we determined the efficacy and safety of minoxidil 2% lotion for eyebrow enhancement compared with placebo. Forty patients were randomized for minoxidil on the eyebrow on one side of the face and placebo on the other. Efficacy was evaluated by global photographic assessment, eyebrow diameter, eyebrow count and subject's satisfaction. Side‐effects were also evaluated. Thirty‐nine patients (97.5%) completed the study. After 16 weeks, the minoxidil group achieved significantly better results in all measured outcomes compared to the placebo group. Side‐effects were minor and did not preclude patients from continuing the study. Our study suggests that minoxidil 2% lotion is a safe and effective treatment for eyebrow hypotrichosis.     

Influence of minoxidil on myocardial hemodynamics,regional blood flow,and morphology in beagle dogs

Summary Studies were made of the effects of two doses of minoxidil (3 mg/kg), given 24 hours apart, on cardiovascular hemodynamics, regional myocardial blood flow, and cardiac morphology in beagle dogs. Minoxidil caused increases in mean right atrial and left ventricular end-diastolic pressure. Systemic and pulmonary vascular resistance were reduced; cardiac output was increased. Left ventricular stroke work and the systolic pressure time index were unchanged by monoxidil administration. The diastolic pressure time index and ratio of diastolic/systolic pressure time index were decreased by minoxidil. Regional myocardial blood flow, measured with radioactive microspheres, increased in all regions of the heart except to the left ventricular papillary muscles. Minoxidil increased blood flow to left ventricular subendocardial tissue; however, this increase was significantly less than that observed in corresponding areas of subepicardial tissue, thus reducing the subendocardial/subepicardial tissue blood flow ratio. These results suggest that minoxidil is an effective peripheral vasodilator but may result in inadequate subendocardial perfusion. Morphologic studies disclosed two types of minoxidil-induced cardiac lesions: left ventricular papillary muscle necroses, and hemorrhagic lesions which were most prominent in right atrium and were associated with inflammation, intramural hemorrhage, and fibrinoid necrosis of small arteries. The papillary muscle necroses were attributed to hypoxia. The atrial lesions were not of ischemic or hypoxic origin, because minoxidil did not decrease blood flow to atrial tissue. It is suggested that the atrial lesions are related to excessive vasodilatation.     

穴位放血疗法联合微针配合米诺地尔治疗进展期雄激素性秃发疗效分析

目的:探讨穴位放血疗法联合微针配合米诺地尔治疗进展期雄激素性秃发的疗效。方法:将2016年1月-2018年1月笔者科室门诊收治的85例男性进展期雄激素性秃发患者随机分成两组,联合组(放血疗法联合微针配合米诺地尔)43例和对照组(微针配合米诺地尔)42例。比较两组患者治疗3个月、6个月后的疗效、毛发密度及血清睾酮(T)、双氢睾酮(DHT)、性激素结合球蛋白(SHBG)及游离睾酮(FT)水平,比较两组患者停药后的复发情况及治疗期间出现的不良反应。结果:治疗3个月、6个月后,联合组患者总有效率均明显高于对照组,终毛密度与总毛发密度均明显高于对照组(P<0.05),毳毛密度与对照组患者相比,差异无统计学意义(P>0.05);治疗3个月、6个月后,联合组患者DHT、FT水平比对照组明显降低,SHBG水平比对照组明显升高(P<0.05);T水平与对照组相比,差异无统计学意义(P>0.05);停药12个月后,联合组患者的总复发率低于对照组患者(P<0.05),联合组患者治疗期间不良反应发生率低于对照组患者(P<0.05)。结论:穴位放血疗法联合微针配合米诺地尔治疗进展期雄激素性秃发患者疗效确切,不仅可以明显增加患者头发密度、降低复发率,还可以平衡患者的性激素,且安全性高。     

快速筛查中草药育发类产品中非法添加米诺地尔的研究

目的建立了一种快速筛查中草药育发类产品中违法添加化学物质米诺地尔的方法,同时建立其液相色谱确证方法。方法采用试管法快速筛查样品中所含米诺地尔,采用液相色谱法对米诺地尔进行定性定量分析。结果 38批次产品中6批次检出米诺地尔。快筛方法的检出限为3.12 mg/mL,液相色谱法测得米诺地尔在0.201~50.360μg/mL时,色谱峰面积与分析浓度呈良好线性关系,检出限（S/N=3）和定量限（S/N=10）分别为0.05μg/mL和0.17μg/mL。加标高、中、低3个浓度水平的回收率分别为101.7%、96.9%和96.6%,RSD分别为2.5%、1.3%和1.3%。结论所建立的快筛方法简便快捷、灵敏度高,液相色谱法专属性强,重现性好,可作为该类产品是否添加米诺地尔的检测方法。     

纳晶微针联合5%米诺地尔酊治疗男性雄激素脱发的临床观察

目的评估纳晶微针联合5%米诺地尔酊治疗男性雄激素脱发(AGA)的治疗效果及安全性.方法于我院皮肤科门诊收集男性AGA患者90例,随机分为3组,各组均30人.纳晶微针联合外用5%米诺地尔酊(A组)、单独纳晶微针治疗组(B组)和单独外用5%米诺地尔酊治疗组(C组),三组患者均连续治疗24周后评估疗效.结果治疗24周后,医师疗效评分方面:A组明显改善率40%,B组和C组明显改善率均为6.7%,三组患者均有改善.两组间相比,A组与B组(P<0.001)、A组与C组(P<0.001),差异均有统计学意义.患者疗效平均分:A组3.03分>C组1.93分>B组1.73分.两组间对比,A组与B组(P<0.001),A组与C组(P<0.001),差异均具有统计学意义.治疗过程中三组患者均未出现明显不良反应.结论纳晶微针联合5%米诺地尔酊治疗男性AGA比单独应用纳晶微针及单独外用米诺地尔治疗效果更佳,值得临床推广应用.     

紫外分光光度法测定米诺地尔酊的含量

目的：用紫外分光光度法测米诺地尔酊中米诺地尔的含量,为该药提供质量控制方法。方法：紫外分光光度法。结果：米诺地尔浓度在０．５～６μｇ·ｍｌ－１范围内吸收度与溶液浓度呈线性关系（ｒ＝０．９９９９,ｎ＝５）,回收率为１００．４％,ＲＳＤ为０．１０％（ｎ＝５）。结论：该法能作为米诺地尔酊含量测定的方法,而且简便、准确、快速。